Medtronic plc (MDT) is scheduled to report third-quarter fiscal 2024 results on Feb 20, before the opening bell.In the last reported quarter, the company’s earnings exceeded the Zacks Consensus Estimate by 5.9%. Medtronic surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 4.46%.Let’s see how things have shaped up prior to this announcement.Factors at PlaySimilar to the last few quarters, Medtronic's business is expected to have registered growth. The upsid ...

股价表现 - Medtronic (MDT) 最新交易日收盘价为$86.18，较前一日下跌了1.12% [1] - Medtronic 过去一个月的股价上涨了0.09%，落后于医疗行业的3.52%和标普500指数的6.45% [2] 财务预测 - Medtronic 即将发布的财报备受投资者关注，预计将于2024年2月20日发布。预计每股收益为$1.26，较去年同期下降了3.08%。目前的市场预期收入为795亿美元，较去年同期增长了2.91% [3] - 根据Zacks Consensus Estimates，整个财年的预计每股收益为5.16美元，营收为320.7亿美元，分别较去年变化了-2.46%和+2.71% [4] 分析师预测 - 投资者应注意最近对Medtronic的分析师预测的变化，这些修订通常反映了最新的短期业务趋势 [5] - 研究表明，这些预测变化与未来股价表现直接相关，Zacks Rank模型考虑了这些预测变化并提供了可操作的评级系统 [6] 股票评级 - Zacks Rank系统从1（强烈买入）到5（强烈卖出），自1988年以来，排名第一的股票年均回报率为+25% [7] - Medtronic目前的Zacks Rank为3（持有） [7] 估值指标 - 目前，Medtronic的前瞻市盈率为16.88，行业平均前瞻市盈率为20.85，意味着Medtronic的股价折价于行业 [8] - MDT目前的PEG比率为3.05，该比率考虑了公司预期的盈利增长率 [9] 行业排名 - 医疗产品行业属于医疗行业，目前的Zacks Industry Rank为169，位于所有250多个行业的底部33% [10] - Zacks Industry Rank通过计算组内个股的平均Zacks Rank来评估各行业群体的实力 [11] 其他信息 - 请继续关注Zacks.com以了解这些影响股价的指标，以及更多信息 [12]

DUBLIN, Feb. 6, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its third quarter of fiscal year 2024 on Tuesday, February 20, 2024. A news release will be issued at approximately 5:45 a.m. Central Standard Time (CST) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's third quarter of fiscal year 2024, which ended on Friday, Januar ...

In the latest trading session, Medtronic (MDT) closed at $86.75, marking a -1% move from the previous day. This move lagged the S&P 500's daily loss of 0.32%. At the same time, the Dow lost 0.71%, and the tech-heavy Nasdaq lost 0.2%.Prior to today's trading, shares of the medical device company had gained 3.62% over the past month. This has outpaced the Medical sector's gain of 2.33% and lagged the S&P 500's gain of 4.59% in that time.Analysts and investors alike will be keeping a close eye on the performan ...

股息股票 - 今天的股息股票在市场指数回到历史高位的情况下逐渐受到欢迎，许多高收入者和长期复利者被定价为折扣购买[1] - 房地产收入公司Realty Income (NYSE:O)因其股息贵族地位、每月分配和5.66%的收益率而成为永久的最爱[3] - AT&T (NYSE:T)定位为领先的增长型股息股票，推动着全球连接未来的边界，同时提供健康的6.48%总收益率[6]

The most recent trading session ended with Medtronic (MDT) standing at $86.97, reflecting a -0.54% shift from the previouse trading day's closing. The stock's change was less than the S&P 500's daily loss of 0.06%. At the same time, the Dow added 0.35%, and the tech-heavy Nasdaq lost 0.76%.The the stock of medical device company has risen by 6.14% in the past month, leading the Medical sector's gain of 1.65% and the S&P 500's gain of 3.36%.Investors will be eagerly watching for the performance of Medtronic ...

Medtronic (MDT) ended the recent trading session at $84.72, demonstrating a -1.88% swing from the preceding day's closing price. This change lagged the S&P 500's daily gain of 0.08%. Elsewhere, the Dow saw a downswing of 0.26%, while the tech-heavy Nasdaq appreciated by 0.36%.Coming into today, shares of the medical device company had gained 4.91% in the past month. In that same time, the Medical sector gained 2.16%, while the S&P 500 gained 2.4%.Market participants will be closely following the financial r ...

公司表现 - Medtronic在过去一年表现不佳，但具有长期增长记录[1] 业务改造 - 公司正在进行业务改造以提高收入增长[5] 股息股票 - Medtronic是一家优秀的股息股票，连续46年增加股息[10]

Medtronic 公司新产品发布 - Medtronic 公司获得 FDA 批准其 Percept RC 深部脑刺激系统，用于缓解帕金森病、肌张力障碍和本体震颤等运动障碍[1][2] - 深部脑刺激（DBS）系统通过向大脑特定区域发送控制的直接电刺激来帮助缓解运动障碍[4] - Percept PC 深部脑刺激系统具有 BrainSense 技术和 SenSight 定向导线，可提供实时大脑数据和精准刺激[6]

Bojan89 Medical device stocks have staged an impressive comeback on both an absolute and relative basis over the past three months. After crumbling compared to the S&P 500 into early October last year, partly due to fears the GLP-1 weight-loss drugs would stymie demand for invasive medical procedures, the group of Health Care sector equities has quickly become market leaders. Medtronic (NYSE:MDT) is up seven sessions in a row to jump-start the year. I reiterate my buy rating on the company. I continue t ...